The US investment bank says the phase 3 results in ovarian cancer change its view of the drug candidate and still point to ...
AbbVie will test lutikizumab together with ABBV-295, the amylin-based obesity drug it licensed from Danish biotech Gubra, ...
China has more house dust mite allergy sufferers than any other country, but fewer than 1 million of an estimated 100 million ...
All major hearing aid makers are launching new premium devices at the same time, but Søren Nielsen expects audiologists to ...
EU panel backs Eli Lilly’s Foundayo obesity pill Eli Lilly is still awaiting final approval from the European Commission.
On Thursday evening, Bioporto was able to delight investors with a US marketing approval for the kidney test NGAL for patients between the ages of three months and 21 years. The US Food and Drug ...
In May, Demant achieved its highest ever market share in the Veterans Affairs (VA) sales channel. This follows the launch of the top product Oticon Intent, which was made available on May 1. And it ...
Novo plans to launch at least five multiblockbusters by 2030 Novo expects to generate sales of DKK 150bn (USD 23bn) in 2035.
ChemoMetec raises outlook after first quarter of fiscal 2026/27 The upward revision comes in response to increased demand, the company says.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results